UY37843A - Inhibidores de mcl-1 macrocíclicos y métodos de uso - Google Patents
Inhibidores de mcl-1 macrocíclicos y métodos de usoInfo
- Publication number
- UY37843A UY37843A UY0001037843A UY37843A UY37843A UY 37843 A UY37843 A UY 37843A UY 0001037843 A UY0001037843 A UY 0001037843A UY 37843 A UY37843 A UY 37843A UY 37843 A UY37843 A UY 37843A
- Authority
- UY
- Uruguay
- Prior art keywords
- mcl
- methods
- macrocyclic inhibitors
- formula
- compounds
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220480121 H/ACA ribonucleoprotein complex subunit DKC1_R10A_mutation Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación proporciona compuestos de fórmula (I), en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de los mismos, que sean útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de fórmula (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545853P | 2017-08-15 | 2017-08-15 | |
| US201762555475P | 2017-09-07 | 2017-09-07 | |
| US201862692663P | 2018-06-30 | 2018-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37843A true UY37843A (es) | 2019-03-29 |
Family
ID=65362347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037843A UY37843A (es) | 2017-08-15 | 2018-08-15 | Inhibidores de mcl-1 macrocíclicos y métodos de uso |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10676485B2 (es) |
| EP (2) | EP3988555A1 (es) |
| JP (1) | JP2020531433A (es) |
| KR (1) | KR20200041942A (es) |
| CN (1) | CN111818917A (es) |
| AU (1) | AU2018316620A1 (es) |
| BR (1) | BR112020003180A2 (es) |
| CA (1) | CA3073112A1 (es) |
| CL (2) | CL2020000363A1 (es) |
| CO (1) | CO2020002678A2 (es) |
| CR (1) | CR20200124A (es) |
| EC (1) | ECSP20018703A (es) |
| IL (1) | IL272681A (es) |
| MX (1) | MX2020001717A (es) |
| PH (1) | PH12020500327A1 (es) |
| RU (1) | RU2020110517A (es) |
| SG (2) | SG10202106345VA (es) |
| TW (1) | TW201920194A (es) |
| UA (1) | UA126586C2 (es) |
| UY (1) | UY37843A (es) |
| WO (1) | WO2019035911A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112739343A (zh) * | 2017-08-15 | 2021-04-30 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
| CN111032046B (zh) | 2017-08-15 | 2023-09-26 | 安吉奥斯医药品有限公司 | 丙酮酸激酶调节剂及其用途 |
| UY37844A (es) * | 2017-08-15 | 2019-03-29 | Abbvie Inc | Inhibidores de mcl-1 macrocíclicos y métodos de uso |
| SG10202106345VA (en) * | 2017-08-15 | 2021-07-29 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
| IL305085A (en) | 2017-09-07 | 2023-10-01 | Univ Res Inst Inc Augusta | A specific AKT3 activator and its uses |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| US20230081720A1 (en) | 2019-05-20 | 2023-03-16 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2276346T3 (en) * | 2008-04-30 | 2017-02-27 | Nat Health Research Institutes | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2017182625A1 (en) | 2016-04-22 | 2017-10-26 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
| TWI759316B (zh) | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 |
| SI3532067T1 (sl) | 2016-10-28 | 2022-09-30 | Les Laboratoires Servier | Liposomska formulacija za uporabo v zdravljenju raka |
| WO2018126898A1 (zh) | 2017-01-05 | 2018-07-12 | 河南美泰宝生物制药有限公司 | 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用 |
| UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
| SG10202106345VA (en) * | 2017-08-15 | 2021-07-29 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
| UY37844A (es) * | 2017-08-15 | 2019-03-29 | Abbvie Inc | Inhibidores de mcl-1 macrocíclicos y métodos de uso |
| CN112739343A (zh) | 2017-08-15 | 2021-04-30 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
| CN107573360B (zh) | 2017-10-27 | 2019-08-09 | 都创(上海)医药科技有限公司 | 一种多靶点小分子化合物s63845的制备方法 |
-
2018
- 2018-08-15 SG SG10202106345VA patent/SG10202106345VA/en unknown
- 2018-08-15 WO PCT/US2018/000180 patent/WO2019035911A1/en unknown
- 2018-08-15 KR KR1020207007568A patent/KR20200041942A/ko not_active Application Discontinuation
- 2018-08-15 UY UY0001037843A patent/UY37843A/es not_active Application Discontinuation
- 2018-08-15 EP EP21197248.4A patent/EP3988555A1/en active Pending
- 2018-08-15 EP EP18846737.7A patent/EP3652184A1/en not_active Withdrawn
- 2018-08-15 JP JP2020508463A patent/JP2020531433A/ja active Pending
- 2018-08-15 CA CA3073112A patent/CA3073112A1/en active Pending
- 2018-08-15 RU RU2020110517A patent/RU2020110517A/ru unknown
- 2018-08-15 AU AU2018316620A patent/AU2018316620A1/en not_active Abandoned
- 2018-08-15 CN CN201880066986.9A patent/CN111818917A/zh active Pending
- 2018-08-15 TW TW107128523A patent/TW201920194A/zh unknown
- 2018-08-15 MX MX2020001717A patent/MX2020001717A/es unknown
- 2018-08-15 SG SG11202001182QA patent/SG11202001182QA/en unknown
- 2018-08-15 US US15/998,789 patent/US10676485B2/en active Active
- 2018-08-15 BR BR112020003180-1A patent/BR112020003180A2/pt unknown
- 2018-08-15 UA UAA202001749A patent/UA126586C2/uk unknown
- 2018-08-15 CR CR20200124A patent/CR20200124A/es unknown
-
2020
- 2020-02-12 CL CL2020000363A patent/CL2020000363A1/es unknown
- 2020-02-13 PH PH12020500327A patent/PH12020500327A1/en unknown
- 2020-02-14 IL IL272681A patent/IL272681A/en unknown
- 2020-03-10 CO CONC2020/0002678A patent/CO2020002678A2/es unknown
- 2020-03-13 EC ECSENADI202018703A patent/ECSP20018703A/es unknown
- 2020-05-11 US US16/872,279 patent/US20200325153A1/en not_active Abandoned
- 2020-11-12 CL CL2020002943A patent/CL2020002943A1/es unknown
-
2022
- 2022-02-03 US US17/649,906 patent/US20230183261A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190144465A1 (en) | 2019-05-16 |
| WO2019035911A1 (en) | 2019-02-21 |
| EP3652184A4 (en) | 2020-05-20 |
| CO2020002678A2 (es) | 2020-08-10 |
| UA126586C2 (uk) | 2022-11-02 |
| KR20200041942A (ko) | 2020-04-22 |
| RU2020110517A (ru) | 2021-09-16 |
| PH12020500327A1 (en) | 2020-10-12 |
| IL272681A (en) | 2020-03-31 |
| SG11202001182QA (en) | 2020-03-30 |
| CL2020002943A1 (es) | 2021-03-12 |
| RU2020110517A3 (es) | 2022-03-23 |
| EP3988555A1 (en) | 2022-04-27 |
| AU2018316620A1 (en) | 2020-03-12 |
| US10676485B2 (en) | 2020-06-09 |
| BR112020003180A2 (pt) | 2020-09-15 |
| CA3073112A1 (en) | 2019-02-21 |
| JP2020531433A (ja) | 2020-11-05 |
| CL2020000363A1 (es) | 2020-06-12 |
| US20230183261A1 (en) | 2023-06-15 |
| EP3652184A1 (en) | 2020-05-20 |
| CR20200124A (es) | 2020-09-28 |
| US20200325153A1 (en) | 2020-10-15 |
| MX2020001717A (es) | 2020-10-08 |
| ECSP20018703A (es) | 2020-04-22 |
| TW201920194A (zh) | 2019-06-01 |
| CN111818917A (zh) | 2020-10-23 |
| SG10202106345VA (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37842A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| UY37843A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| UY37844A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| UY39630A (es) | Inhibidores de bromodominios | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
| UY37205A (es) | Inhibidores de bromodominios | |
| CR20160035A (es) | Inhibidores de bromodominios | |
| PE20151788A1 (es) | Inhibidores de bromodominios tetraciclicos | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| UY36123A (es) | Derivados de carboxamida | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| ECSP18056196A (es) | Derivados de indano | |
| CL2016002870A1 (es) | Derivados bicíclicos y composición farmacéutica que incluye los mismos | |
| UY36958A (es) | Compuestos para administración intracelular | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| CU20160170A7 (es) | Derivados de carboxamida | |
| TR201900156T4 (tr) | Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20231110 |